State‐of‐the‐art immunogenicity evaluation in phase 3 confirmatory study (EGALITY ) with etanercept biosimilar GP 2015
Volume: 32, Issue: 4
Published: Nov 6, 2017
Abstract
Journal of the European Academy of Dermatology and VenereologyVolume 32, Issue 4 p. e130-e132 Letter to the Editor State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015 J. Poetzl, Corresponding Author J. Poetzl johann.poetzl@sandoz.com Bioanalytics, Hexal AG, Oberhaching, GermanyCorrespondence: J. Poetzl. Email: johann.poetzl@sandoz.comSearch for more papers by this authorI. Arlt, I....
Paper Details
Title
State‐of‐the‐art immunogenicity evaluation in phase 3 confirmatory study (EGALITY ) with etanercept biosimilar GP 2015
Published Date
Nov 6, 2017
Volume
32
Issue
4
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History